Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 1 » Issue 1

Lower limb vasodilatory capacity is not reduced in patients with moderate COPD

Authors Surendran Sabapathy, Marc F Awater, Donald A Schneider, Rebecca A Kingsley, Maria TE Hopman, Norman R Morris

Published Date May 2006 Volume 2006:1(1) Pages 73—81

DOI

Published 4 May 2006

Surendran Sabapathy1, Marc F Awater2, Donald A Schneider1, Rebecca A Kingsley1, Maria TE Hopman2, Norman R Morris1

1School of Physiotherapy and Exercise Science, and Heart Foundation Research Centre, Gold Coast campus, Griffith University, QLD, Australia; 2Department of Physiology, University of Nijmegen, Nijmegen, The Netherlands

Abstract: We compared exercise capacity (peak O2 uptake; VO2peak) and lower limb vasodilatory capacity in 9 patients with moderate COPD (FEV1 52.7 ± 7.6% predicted) and 9 age-matched healthy control subjects.  VO2peak was measured via open circuit spirometry during incremental cycling. Calf blood flow (CBF) measurements were obtained at rest and after 5 minutes of ischemia using venous occlusion plethysmography. While VO2peak was significantly lower in the COPD patients (15.8 ± 3.5 mL·kg–1·min–1) compared with the control group (25.2 ± 3.5 mL·kg–1·min–1), there were no significant differences between groups in peak CBF or peak calf conductance measured 7 seconds post-ischemia. VO2peak was significantly correlated with peak CBF and peak conductance in the control group, whereas no significant relationship was found between these variables in the COPD group. However, the rate of decay in blood flow following ischemia was significantly slower (p < 0.05) for the COPD group (–0.036 ± 0.005 mL·100 mL–1·min–1·s–1) when compared with controls (–0.048 ± 0.015 mL·100mL–1·min–1·s–1). The results suggest that the lower peak exercise capacity in patients with moderate COPD is not related to a loss in leg vasodilatory capacity.

Keywords: obstructive lung disease, exercise capacity, reactive hyperemia, calf blood flow

Download Article [PDF] 

Readers of this article also read:

Antioxidant therapies in COPD

Irfan Rahman

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:15-29

Published Date: 4 May 2006

Role of mucolytics in the management of COPD

Phillippa J Poole

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:123-128

Published Date: 4 May 2006

Emerging role of MAP kinase pathways as therapeutic targets in COPD

Becky A Mercer, Jeanine M D’Armiento

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:137-150

Published Date: 4 May 2006

Editorial: COPD: The end of the beginning ||FREE PAPER||

Richard Russell, Dave Singh, Irfan Rahman, Alan J Crockett

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:1-1

Published Date: 22 April 2006

Akt in the pathogenesis of COPD

Steven Bozinovski, Ross Vlahos, Michelle Hansen, Ken Liu, Gary P Anderson

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:31-38

Published Date: 18 February 2006

Eosinophilic airway inflammation in COPD

Shironjit Saha, Christopher E Brightling

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:39-47

Published Date: 18 February 2006